Physician profile
Javier Puentes
NPI 1679946982
$3,308.46
in general payments reported to CMS, 2019-2025
17 companies · $465 in 2025
The $465 reported for 2025 was more than what 83% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2021: $78.29 · 2022: $238 · 2023: $592 · 2024: $1,797 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,853.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $719.79 | 2024-2025 | Voquezna |
| Amgen INC. | $642.79 | 2023-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $604.63 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $497.90 | 2021-2024 | Xarelto |
| Exact Sciences Corporation | $190.45 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $144.48 | 2019-2024 | |
| Lilly USA, LLC | $99.88 | 2024-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $81.22 | 2023-2024 | |
| Inspire Medical Systems, INC. | $71.14 | 2024 | Inspire |
| Kowa Pharmaceuticals America, INC. | $52.97 | 2024-2025 | Zoryve |
| Evoke Pharma, INC. | $49.17 | 2024-2025 | |
| Abbott Laboratories | $42.71 | 2022-2023 | Freestyle Libre |
| Hologic Sales and Service, LLC | $25.49 | 2024 | Aptima, Thinprep 2000 Processor |
| Optinose US, INC. | $23.94 | 2025 | |
| Ironshore Pharmaceuticals INC. | $22.86 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $20.46 | 2021 | |
| Phadia US INC. | $18.58 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Puentes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.